Pharmaceutical Technology1 个月
Taletrectinib adipate by Nuvation Bio for Solid Tumor: Likelihood of Approval
Taletrectinib adipate is under clinical development by Nuvation Bio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success ...
Pharmaceutical Technology1 个月
Itacitinib adipate by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Itacitinib adipate (INCB-39110) is under development for the treatment ...